181 related articles for article (PubMed ID: 23426901)
41. SOCS-1/3 participation in FGF-2 signaling to modulate RANK ligand expression in paget's disease of bone.
Sundaram K; Senn J; Reddy SV
J Cell Biochem; 2013 Sep; 114(9):2032-8. PubMed ID: 23553658
[TBL] [Abstract][Full Text] [Related]
42. ADAM8 enhances osteoclast precursor fusion and osteoclast formation in vitro and in vivo.
Ishizuka H; García-Palacios V; Lu G; Subler MA; Zhang H; Boykin CS; Choi SJ; Zhao L; Patrene K; Galson DL; Blair HC; Hadi TM; Windle JJ; Kurihara N; Roodman GD
J Bone Miner Res; 2011 Jan; 26(1):169-81. PubMed ID: 20683884
[TBL] [Abstract][Full Text] [Related]
43. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
44. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis.
Grcević D; Lee SK; Marusić A; Lorenzo JA
J Immunol; 2000 Oct; 165(8):4231-8. PubMed ID: 11035056
[TBL] [Abstract][Full Text] [Related]
45. Etiology of Paget's disease and osteoclast abnormalities.
Reddy SV
J Cell Biochem; 2004 Nov; 93(4):688-96. PubMed ID: 15389972
[TBL] [Abstract][Full Text] [Related]
46. 1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells.
Ishizuka S; Kurihara N; Hiruma Y; Miura D; Namekawa J; Tamura A; Kato-Nakamura Y; Nakano Y; Takenouchi K; Hashimoto Y; Nagasawa K; Roodman GD
J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):269-77. PubMed ID: 18501591
[TBL] [Abstract][Full Text] [Related]
47. Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-κB ligand expression in osteoblasts.
Tachi K; Takami M; Zhao B; Mochizuki A; Yamada A; Miyamoto Y; Inoue T; Baba K; Kamijo R
Cell Tissue Res; 2010 Nov; 342(2):213-20. PubMed ID: 20941510
[TBL] [Abstract][Full Text] [Related]
48. Studies in Paget's disease and their relevance to oncology.
Roodman GD
Semin Oncol; 2001 Aug; 28(4 Suppl 11):15-21. PubMed ID: 11544571
[TBL] [Abstract][Full Text] [Related]
49. Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol.
Chow EC; Magomedova L; Quach HP; Patel R; Durk MR; Fan J; Maeng HJ; Irondi K; Anakk S; Moore DD; Cummins CL; Pang KS
Gastroenterology; 2014 Apr; 146(4):1048-59. PubMed ID: 24365583
[TBL] [Abstract][Full Text] [Related]
50. Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3-24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D3.
Zou A; Elgort MG; Allegretto EA
J Biol Chem; 1997 Jul; 272(30):19027-34. PubMed ID: 9228086
[TBL] [Abstract][Full Text] [Related]
51. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
[TBL] [Abstract][Full Text] [Related]
52. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
53. Basic fibroblast growth factor induces osteoclast formation in murine bone marrow cultures.
Hurley MM; Lee SK; Raisz LG; Bernecker P; Lorenzo J
Bone; 1998 Apr; 22(4):309-16. PubMed ID: 9556129
[TBL] [Abstract][Full Text] [Related]
54. Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sections.
Mee AP; Hoyland JA; Braidman IP; Freemont AJ; Davies M; Mawer EB
Bone; 1996 Apr; 18(4):295-9. PubMed ID: 8726384
[TBL] [Abstract][Full Text] [Related]
55. Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment.
Choi SJ; Kurihara N; Oba Y; Roodman GD
J Bone Miner Res; 2001 Oct; 16(10):1804-11. PubMed ID: 11585344
[TBL] [Abstract][Full Text] [Related]
56. New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone.
Haussler MR; Jurutka PW; Hsieh JC; Thompson PD; Selznick SH; Haussler CA; Whitfield GK
Bone; 1995 Aug; 17(2 Suppl):33S-38S. PubMed ID: 8579895
[TBL] [Abstract][Full Text] [Related]
57. Direct repeat 3-type element lacking the ability to bind to the vitamin D receptor enhances the function of a vitamin D-responsive element.
Ozono K; Yamagata M; Ohyama Y; Nakajima S
J Steroid Biochem Mol Biol; 1998 Sep; 66(5-6):263-9. PubMed ID: 9749832
[TBL] [Abstract][Full Text] [Related]
58. Regulation of mouse Cyp24a1 expression via promoter-proximal and downstream-distal enhancers highlights new concepts of 1,25-dihydroxyvitamin D(3) action.
Pike JW; Meyer MB
Arch Biochem Biophys; 2012 Jul; 523(1):2-8. PubMed ID: 22179019
[TBL] [Abstract][Full Text] [Related]
59. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
60. p38beta2-mediated phosphorylation and sumoylation of ATF7 are mutually exclusive.
Camuzeaux B; Diring J; Hamard PJ; Oulad-Abdelghani M; Donzeau M; Vigneron M; Kedinger C; Chatton B
J Mol Biol; 2008 Dec; 384(4):980-91. PubMed ID: 18950637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
